Biotech Group Acquisition Corp

Biotech Group Acquisition Corp (Nasdaq: BGAC) is a blank-check company formed to pursue a merger, capital stock exchange, or similar business combination with a target in the biotechnology and life sciences sector. The company filed an amended registration statement (S-1/A) with the SEC on June 7, 2023, accession number 0001213900-23-047127, as part of its IPO process, placing its debut in the 2023 SPAC class. The vehicle is structured to identify and acquire a business operating within the biotech industry, reflecting continued investor appetite for healthcare-focused acquisition vehicles despite a broader pullback in SPAC activity. For the full sponsor profile, deal timeline, pipe terms, and real-time status updates on BGAC, create a free account at SpacDesk.